| Summary: |
Mineralocorticoid receptor antagonists (MRAs) may be candidates for reducing myocardial fi brosis (MF). Finerenone is a new non-steroidal MRA that is highly selective for the myocardium. FIBROFINE aims to study, through a randomised placebo-controlled clinical trial, a potential new application for fi nerenone: reduction of FM in patients at high cardiovascular risk. |